Abstract
We investigated the effect of 0.05% topical cyclosporine (Cys) on the ocular surface and tear functions in dry eye patients with chronic GVHD (cGVHD) in a prospective comparative study. Thirty eyes of 15 patients refractory to baseline treatment were recruited and the patients assigned for topical Cys treatment group (14 eyes of 7 patients) and control group (12 eyes of 6 patients) respectively. Two patients dropped out because of intolerable irritation while using topical Cys eye drops. Visual analog scale symptom scores, corneal sensitivity, Schirmer I test value, tear film break-up time (TBUT), tear evaporation rate and ocular surface vital staining scores were recorded at baseline and at the end of the following one month. Conjunctival impression and brush cytology were performed before and after the treatment. After topical Cys treatment, significant improvements were found in symptom scores, corneal sensitivity, tear evaporation rate, TBUT, vital staining scores, goblet cells density, conjunctival squamous metaplasia grade, inflammatory cell numbers and the MUC5AC expression. Our study suggests that 0.05% topical Cys may be an effective treatment for dry eye patients with cGVHD. The improvements in the ocular surface and tear functions resulted presumably from the decreased inflammation, increased goblet cell density and MUC5AC mRNA expression.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Horowitz M . Uses and growth of hematopoietic cell transplantation immunology. In: Blume KG, Forman SJ, Applebaum FR (eds). Thomas' Hematopoietic Cell Transplantation, 3rd edn. Blackwell: Malden, MA, 2004, pp 9–15.
Martin PJ . Overview of hematopoietic cell transplantation. In: Blume KG, Forman SJ, Applebaum FR (eds). Thomas' Hematopoietic Cell Transplantation, 3rd edn. Blackwell: Malden, MA, 2004, pp 16–30.
Ogawa Y, Kuwana M . Dry eye as a major complication associated with chronic graft-versus-host disease after hematopoietic stem cell transplantation. Cornea 2003; 22: S19–S27.
Franklin RM, Kenyon KR, Tutschka PJ, Saral R, Green WR, Santos GW . Ocular manifestations of graft-vs-host disease. Ophthalmology 1983; 90: 4–13.
Ogawa Y, Okamoto S, Wakui M, Watanabe R, Yamada M, Yoshino M et al. Dry eye after hematopoietic stem cell transplantation. Br J Ophthalmol 1999; 83: 1125–1130.
Hirst LW, Jabs DA, Tutschka PJ, Green WR, Santos GW . The eye in bone marrow transplantation. I. Clinical study. Arch Ophthalmol 1983; 101: 580–584.
Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204–217.
Mencucci R, Rossi Ferrini C, Bosi A, Volpe R, Guidi S, Salvi G . Ophthalmological aspects in allogenic bone marrow transplantation: Sjogren-like syndrome in graft-versus-host disease. Eur J Ophthalmol 1997; 7: 13–18.
Tichelli A, Duell T, Weiss M, Socie G, Ljungman P, Cohen A et al. Late-onset keratoconjunctivitis sicca syndrome after bone marrow transplantation: incidence and risk factors. European group for blood and marrow transplantation (EBMT) Working party on late effects. Bone Marrow Transplant 1996; 17: 1105–1111.
Ogawa Y, Okamoto S, Mori T, Yamada M, Mashima Y, Watanabe R et al. Autologous serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease. Bone Marrow Transplant 2003; 31: 579–583.
Murphy PT, Sivakumaran M, Fahy G, Hutchinson RM . Successful use of topical retinoic acid in severe dry eye due to chronic graft-versus-host disease. Bone Marrow Transplant 1996; 18: 641–642.
Rocha EM, Pelegrino FS, de Paiva CS, Vigorito AC, de Souza CA . GVHD dry eyes treated with autologous serum tears. Bone Marrow Transplant 2000; 25: 1101–1103.
Ogawa Y, Okamoto S, Kuwana M, Mori T, Watanabe R, Nakajima T et al. Successful treatment of dry eye in two patients with chronic graft versus host disease with systemic administration of FK506 and corticosteroids. Cornea 2001; 20: 430–434.
Sall K, Stevenson OD, Mundorf TK, Reis BL . Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology 2000; 107: 631–639.
Stevenson D, Tauber J, Reis BL . Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The cyclosporin A phase 2 study group. Ophthalmology 2000; 107: 967–974.
Barber LD, Pflugfelder SC, Tauber J, Foulks GN . Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Ophthalmology 2005; 112: 1790–1794.
Shimazaki J, Goto E, Ono M, Shimmura S, Tsubota K . Meibomian gland dysfunction in patients with Sjogren syndrome. Ophthalmology 1998; 105: 1485–1488.
Kojima T, Ishida R, Dogru M, Goto E, Matsumoto Y, Kaido M et al. The effect of autologous serum eyedrops in the treatment of severe dry eye disease: a prospective randomized case-control study. Am J Ophthalmol 2005; 139: 242–246.
Tsubota K, Yamada M . Tear evaporation from the ocular surface. Invest Ophthalmol Vis Sci 1992; 33: 2942–2950.
Goto E, Endo K, Suzuki A, Fujikura Y, Matsumoto Y, Tsubota K et al. Tear evaporation dynamics in normal subjects and subjects with obstructive meibomian gland dysfunction. Invest Ophthalmol Vis Sci 2003; 44: 533–539.
Toda I, Tsubota K . Practical double vital staining for ocular surface evaluation. Cornea 1993; 12: 366–367.
Nelson JD . Impression cytology. Cornea 1988; 7: 71–81.
Dogru M, Asano-Kato N, Tanaka M, Igarashi A, Shimmura S, Shimazaki J et al. Ocular surface and MUC5AC alterations in atopic patients with corneal shield ulcers. Curr Eye Res 2005; 30: 897–908.
Miyoshi T, Fukagawa K, Shimmura S, Fujishima H, Takano Y, Takamura E et al. Interleukin-8 concentrations in conjunctival epithelium brush cytology samples correlate with neutrophil, eosinophil infiltration, and corneal damage. Cornea 2001; 20: 743–747.
Pflugfelder SC . Anti-inflammatory therapy of dry eye. Ocul Surf 2003; 1: 31–36.
Nishida T . Neurotrophic mediators and corneal wound healing. Ocul Surf 2005; 3: 194–202.
Kunert KS, Tisdale AS, Gipson IK . Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch Ophthalmol 2002; 120: 330–337.
Wilson SE, Perry HD . Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment. Ophthalmology 2007; 114: 76–79.
Tatlipinar S, Akpek EK . Topical cyclosporin in the treatment of ocular surface disorders. Br J Ophthalmol 2005; 89: 1363–1367.
Rao SN, Rao RD . Efficacy of topical cyclosporine 0.05% in the treatment of dry eye associated with graft versus host disease. Cornea 2006; 25: 674–678.
Lelli Jr GJ, Musch DC, Gupta A, Farjo QA, Nairus TM, Mian SI et al. Ophthalmic cyclosporine use in ocular GVHD. Cornea 2006; 25: 635–638.
Ogawa Y, Kuwana M, Yamazaki K, Mashima Y, Yamada M, Mori T et al. Periductal area as the primary site for T-cell activation in lacrimal gland chronic graft-versus-host disease. Invest Ophthalmol Vis Sci 2003; 44: 1888–1896.
Ogawa Y, Yamazaki K, Kuwana M, Mashima Y, Nakamura Y, Ishida S et al. A significant role of stromal fibroblasts in rapidly progressive dry eye in patients with chronic GVHD. Invest Ophthalmol Vis Sci 2001; 42: 111–119.
Duncan N, Craddock C . Optimizing the use of cyclosporin in allogeneic stem cell transplantation. Bone Marrow Transplant 2006; 38: 169–174.
Tsubota K, Fujita H, Tadano K, Takeuchi T, Murakami T, Saito I et al. Improvement of lacrimal function by topical application of CyA in murine models of Sjögren's syndrome. Invest Ophthalmol Vis Sci 2001; 42: 101–110.
Tsubota K, Saito I, Ishimaru N, Hayashi Y . Use of topical cyclosporin A in a primary Sjögren's syndrome mouse model. Invest Ophthalmol Vis Sci 1998; 39: 1551–1559.
Acknowledgements
The authors have no proprietary interest in any of the products mentioned in the manuscript. Presented in part at the 60th Japan Congress of Clinical Ophthalmology, 5–8 October 2006, Kyoto, Japan in the same name as this manuscript, ‘’Ocular Surface and Tear Functions after Topical Cyclosporine Treatment in Dry Eye Patients with Chronic Graft-Versus-Host Disease'. Work supported by a grant from the Japanese Ministry of Education, Science, Sports and Culture #18591932. Dr Wang and Dr Ogawa contributed equally to the current work and should be considered of double first authors.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wang, Y., Ogawa, Y., Dogru, M. et al. Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease. Bone Marrow Transplant 41, 293–302 (2008). https://doi.org/10.1038/sj.bmt.1705900
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705900
Keywords
This article is cited by
-
Advances in the ocular complications after hematopoietic stem cell transplantation
Annals of Hematology (2024)
-
The ocular graft-versus-host disease: the path from current knowledge to future managements
Eye (2023)
-
Conjunctival T Cell Profile in Allogeneic Hematopoietic Stem Cell Transplant Patients after Instilling Topical Cyclosporine-A 0.1% Cationic Emulsion
Ophthalmology and Therapy (2023)
-
Ocular surface system alterations in ocular graft-versus-host disease: all the pieces of the complex puzzle
Graefe's Archive for Clinical and Experimental Ophthalmology (2019)
-
Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT
Bone Marrow Transplantation (2019)